CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target ...

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 24.06% and 90.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock ...

Editas Medicine (EDIT) has been downgraded to market perform from outperform by Raymond James due in part to extended ...

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

After reaching an important support level, CRISPR Therapeutics AG (CRSP) could be a good stock pick from a technical perspective. CRSP surpassed resistance at the 50-day moving average, suggesting a ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands ...

Here are seven of the best Vanguard index funds to buy today: ...